Wouldn't the success rate of treatments be of greater importance than the actual number of treatments? If, for example, the recovery (success) rate is high then surely such success warrants Ryoncil as being the treatment "of necessity" rather than choice. I am happy to be enlightened to an alternative. GLTAH Keith
- Forums
- ASX - By Stock
- Ann: Mesoblast Maintains Momentum with FDA
MSB
mesoblast limited
Add to My Watchlist
2.97%
!
$1.80

Wouldn't the success rate of treatments be of greater importance...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.80 |
Change
-0.055(2.97%) |
Mkt cap ! $2.293B |
Open | High | Low | Value | Volume |
$1.84 | $1.86 | $1.77 | $7.241M | 4.018M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 25472 | $1.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.81 | 1500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 485 | 1.780 |
4 | 100773 | 1.770 |
2 | 25500 | 1.765 |
3 | 23000 | 1.760 |
7 | 44464 | 1.750 |
Price($) | Vol. | No. |
---|---|---|
1.805 | 1500 | 1 |
1.810 | 9500 | 1 |
1.820 | 4000 | 1 |
1.835 | 10000 | 1 |
1.840 | 5000 | 1 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |